Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ionis Pharmaceuticals (IONS) -- Ignore unavailable to you. Want to Upgrade?

To: Rob J who wrote (1348)	12/3/1997 5:17:00 PM
From: sds	Read Replies (1) \| Respond to of 4676

Nothing else really matters right now... The only thing that matters with this stock/co. right now is Formavirsen. There's no future, no past -- just that. If it makes it through trials and then through the NDA hoops, this stock will start to get its due. If something should go wrong with the trials, then this is probably a sub-10 stock. Unfortunately, ISIS really hasn't benefited much from the recent biotech rally. I'm pretty confident however, that once the data on Formavirsen is in (and is positive!), this stock will move in a hurry. With all of the shorts lined up, there could be a massive squeeze. Soooo.... in the meantime, forget the reports. Portfolio managers know this story and they know that the story revolves around Formavirsen. Until then, I really think that analysts' ratings aren't going to matter much at all. Afterwards, though.... Does anyone know off-hand when we should hear about Formavirsen? I know I should know, but I can't recall right now... sds

To: Rob J who wrote (1348)	12/4/1997 3:06:00 PM
From: Brian Channon	Respond to of 4676

Re: Zacks Rating Unless thy have change their methodology, Zack considers only two factors whe making their rating. They are 1) earnings surprises (disappoinments); an 2) upward (downward) revisions in earnings estimates submitted by the brokerge firm anlysts that follow the company. To the best of my knowledge, Zacks does not in any way consider the brokerage firm recommendations, except insofar as the aforementioned factors have influenced the brokerage firm recommendations.